Matthews Philippa C, Campbell Cori, Săndulescu Oana, Matičič Mojca, Ruta Simona Maria, Rivero-Juárez Antonio, van Welzen Berend Joost, Tan Boun Kim, Garcia Federico, Gherlan George Sebastian, Çınar Güle, Hasanoğlu İmran, Gmizić Ivana, Nicolini Laura Ambra, Santos Lurdes, Sargsyants Narina, Velikov Petar, Habibović Selma, Fourati Slim, Židovec-Lepej Snježana, Herder Vanessa, Dudman Susanne, Miron Victor Daniel, Irving William, Şahin Gülşen Özkaya
The Francis Crick Institute, London, United Kingdom.
Division of Infection and Immunity, University College London, London, United Kingdom.
Front Pharmacol. 2022 Nov 25;13:1062408. doi: 10.3389/fphar.2022.1062408. eCollection 2022.
During the first half of 2022, the World Health Organization reported an outbreak of acute severe hepatitis of unknown aetiology (AS-Hep-UA) in children, following initial alerts from the United Kingdom (UK) where a cluster of cases was first observed in previously well children aged <6 years. Sporadic cases were then reported across Europe and worldwide, although in most countries incidence did not increase above the expected baseline. There were no consistent epidemiological links between cases, and microbiological investigations ruled out known infectious causes of hepatitis. In this review, we explore the evidence for the role of viral infection, superimposed on a specific host genetic background, as a trigger for liver pathology. This hypothesis is based on a high prevalence of Human Adenovirus (HAdV) 41F in affected children, together with metagenomic evidence of adeno-associated virus (Adeno-associated viruses)-2, which is a putative trigger for an immune-mediated liver injury. Roles for superantigen-mediated pathology have also been explored, with a focus on the potential contribution of SARS-CoV-2 infection. Affected children also had a high frequency of the MHC allele HLA-DRB1*04:01, supporting an immunological predisposition, and may have been vulnerable to viral coinfections due to disruption in normal patterns of exposure and immunity as a result of population lockdowns during the COVID-19 pandemic. We discuss areas of ongoing uncertainty, and highlight the need for ongoing scrutiny to inform clinical and public health interventions for this outbreak and for others that may evolve in future.
2022年上半年,世界卫生组织报告了儿童不明病因急性重症肝炎(AS-Hep-UA)的疫情,此前英国发出了最初警报,在英国首次在6岁以下此前健康的儿童中发现了一组病例。随后欧洲和全球都报告了散发病例,不过在大多数国家,发病率并未超过预期基线。病例之间没有一致的流行病学联系,微生物学调查排除了已知的肝炎感染病因。在本综述中,我们探讨病毒感染在特定宿主遗传背景下作为肝脏病变触发因素的作用证据。这一假设基于受影响儿童中人类腺病毒(HAdV)41F的高流行率,以及腺相关病毒2的宏基因组学证据,腺相关病毒2被认为是免疫介导肝损伤的触发因素。还探讨了超抗原介导病变的作用,重点是严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染的潜在影响。受影响儿童中主要组织相容性复合体(MHC)等位基因HLA-DRB1*04:01的频率也很高,这支持了免疫易感性,并且由于2019冠状病毒病大流行期间实施人口封锁导致正常接触和免疫模式中断,他们可能易发生病毒合并感染。我们讨论了目前仍存在不确定性的领域,并强调需要持续审查,以为此次疫情以及未来可能出现的其他疫情的临床和公共卫生干预提供依据。